The Trump Administration's Latest Drug Pricing Initiatives

By Tom Bulleit, Deborah Gardner, Kirsten Mayer and Scott Falin (January 14, 2019, 3:38 PM EST) -- Donald Trump's election in 2016 placed pharmaceutical companies in uncharted territory. Unlike predecessors from both major political parties, Trump did not shy away from directly criticizing the industry. Whether better seen as creating, or capitalizing on, widespread dissatisfaction with drug prices, President-elect Trump claimed that pharmaceutical companies were "getting away with murder" and promised to take action upon entering office.[1] He went so far as to support the highly controversial idea of allowing the federal government to directly negotiate drug prices with the manufacturers.[2]

After the first year of the Trump administration, industry likely breathed a sigh of relief. While the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!